icell cardiomyocytes (iCell Gene Therapeutics)
90
Structured Review
iCell Gene Therapeutics
icell cardiomyocytes
Icell Cardiomyocytes, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/icell+cardiomyocytes/icell+cardiomyocytes/pmc12263785-72-1-1
Average 90 stars, based on 1 article reviews
Icell Cardiomyocytes, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/icell+cardiomyocytes/icell+cardiomyocytes/pmc12263785-72-1-1
Average 90 stars, based on 1 article reviews
icell cardiomyocytes - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Identifying and establishing the critical elements of a human cardiac in-vitro model for studying type-II diabetes"
Article Title: Identifying and establishing the critical elements of a human cardiac in-vitro model for studying type-II diabetes
Journal: Discover Applied Sciences
doi: 10.1007/s42452-025-07442-y
Figure Legend Snippet: Dose dependent effects of AGEs on AC16 cardiomyocytes. The varying doses applied included 100 µg, 250 and 500 µg for 24 h after which the cells were washed and replenished with complete growth medium. A live cell staining assay was performed to assess the effects of the varying doses of AGEs shown above. Scale bar indicates 100 μm
Techniques Used: Staining
Figure Legend Snippet: Expression Fold Change for gene expression of Cx-43 (encoded by GJA1) in AC16 cardiomyocytes after 48 h of AGEs exposure and post washouts. Data is represented as a normalized relative fold change to control. p-values between control and AGEs or AGEs washouts were significant (0.02) however in between AGEs and AGEs washout no significance was noted
Techniques Used: Expressing, Gene Expression, Control
Figure Legend Snippet: AC16 Cardiomyocytes Cardiac Myosin Heavy Chain (MHC) immunostaining for different experimental conditions: ( A ) Control, ( B ) AGEs, ( C ) Glucose Shock (50 mM), ( D ) AGEs followed by Glucose Shock, ( E ) Inhibitor followed by AGEs, ( F ) Inhibitor followed by AGEs and Glucose Shock. ( G ) Shows the expression levels of cardiac MHC calculated, data is represented as a normalized mean intensity to control. * Represents p < 0.05
Techniques Used: Immunostaining, Control, Expressing
Figure Legend Snippet: AC16 Cardiomyocytes Connexin 43 (Cx-43) immunostaining for different experimental conditions: ( A ) Control, ( B ) AGEs, ( C ) Glucose Shock (50 mM), ( D ) AGEs followed by Glucose Shock, ( E ) Inhibitor followed by AGEs, ( F ) Inhibitor followed by AGEs and Glucose Shock. ( G ) Shows the expression levels of Cx-43 calculated, data is represented as a normalized relative mean intensity to control. * Represents p < 0.05
Techniques Used: Immunostaining, Control, Expressing
Figure Legend Snippet: AC16 Cardiomyocytes RAGE expression for different experimental conditions: ( A ) Control, ( B ) AGEs (500 µg/ml), ( C ) Glucose Shock (50 mM), ( D ) AGEs followed by Glucose Shock, ( E ) Shows the expression levels of RAGE calculated, data is represented as a normalized relative mean intensity to DAPI. * Represents p < 0.05
Techniques Used: Expressing, Control
Figure Legend Snippet: Expression Fold Change for gene expression of Cx-43 (encoded by GJA1) in AC16 cardiomyocytes under different experimental conditions after 24 h of exposure. Data is represented as a normalized relative fold change to control. * Represents p < 0.05
Techniques Used: Expressing, Gene Expression, Control
Figure Legend Snippet: Dose dependent effects of AGEs on iCell Cardiomyocytes. The varying doses applied included ( A ) control, ( B ) 100 µg/ml, ( C ) 250 µg/ml, and ( D ) 500 µg/ml for 30 min after which the cells were washed and replenished with complete growth medium. ( E ) Shows the percentage cell viability measured from the live dead assay performed to assess the effects of the varying doses of AGEs.
Techniques Used: Control, Live Dead Assay
Figure Legend Snippet: Beat Rate heat maps and waveforms studied in relation with dose dependent effects of AGEs on iCell Cardiomyocytes. Image shows applied AGEs at a 100 µg/ml concentration for 30 min after which their contractility characterization was performed. Controls included wells with cells that did not receive any treatments and were washed and replenished with complete growth medium. The figure labels are as follows: ( A ) Control (Scale: 0 to 76), ( B ) AGEs (Scale: 0 to 56), ( C ) AGEs + Glucose Shock (Scale: 0 to 70), ( D ) AGEs Inhibitor + AGEs (Scale: 0 to 56), and ( E ) AGEs Inhibitor + AGEs 100 µg/ml + Glucose Shock (Scale: 0 to 70)
Techniques Used: Concentration Assay, Control
Figure Legend Snippet: Beat Rate heat maps and waveforms studied in relation with dose dependent effects of AGEs on iCell Cardiomyocytes. Image shows applied AGEs at a 250 µg/ml concentration for 30 min after which their contractility characterization was performed. Controls included wells with cells that did not receive any treatments and were washed and replenished with complete growth medium. The figure labels are as follows: ( A ) Control (Scale: 0 to 76), ( B ) AGEs (Scale: 0 to 42), ( C ) AGEs + Glucose Shock (Scale: 0 to 71), ( D ) AGEs Inhibitor + AGEs (Scale: 0 to 42), and ( E ) AGEs Inhibitor + AGEs 250 µg/ml + Glucose Shock (Scale: 0 to 71)
Techniques Used: Concentration Assay, Control
Figure Legend Snippet: Beats per minute (BPM) or cardiac contractile behavior studied in relation with dose dependent effects of AGES on iCell Cardiomyocytes. The varying doses applied included 100 and 250 µg/ml for 30 min after which they were recorded. Controls included wells with cells that did not receive any treatments and were washed and replenished with complete growth medium. * Represents p < 0.05
Techniques Used:
Figure Legend Snippet: iCell Cardiomyocytes control wells (no treatments): ( A ) Brightfield, ( B ) immunostaining and ( C ) RT-PCR of Cardiac MHC (encoded by MYH7)
Techniques Used: Control, Immunostaining, Reverse Transcription Polymerase Chain Reaction
Related Articles
Proliferation Assay:Article Title: Multi-omic analysis reveals VEGFR2, PI3K, and JNK mediate the small molecule induction of human iPSC-derived cardiomyocyte proliferation. Article Snippet: RESULTS Diverse lead compounds induce proliferation without multinucleation or polyploidy in hiPSC-cardiomyocytes To investigate coremechanisms driving proliferation in human iPSC-derived cardiomyocytes (hiPSC-CMs), we selected five highly active compounds with diverse putative targets from a previous study that screened for DNA synthesis, proliferation, and endoreplication.11 AstraZeneca’s target annotation data indicated the lead compounds targeted WNT, BRAF, ALK5 (RepSox), CB1R (AZD2691), and COX-1/ 5-LO (Table 1). .. Using the same live-cell proliferation assay we developed in the previous study,11 we confirmed the 5-point concentrationresponse profiles (0.1–10.0 mM) in three independentmanufacturing lots of Article Title: Multi-omic analysis reveals VEGFR2, PI3K, and JNK mediate the small molecule induction of human iPSC-derived cardiomyocyte proliferation Article Snippet: AstraZeneca’s target annotation data indicated the lead compounds targeted WNT, BRAF, ALK5 (RepSox), CB1R (AZD2691), and COX-1/5-LO ( ). .. Using the same live-cell proliferation assay we developed in the previous study, we confirmed the 5-point concentration-response profiles (0.1–10.0 μM) in three independent manufacturing lots of Concentration Assay:Article Title: Multi-omic analysis reveals VEGFR2, PI3K, and JNK mediate the small molecule induction of human iPSC-derived cardiomyocyte proliferation Article Snippet: AstraZeneca’s target annotation data indicated the lead compounds targeted WNT, BRAF, ALK5 (RepSox), CB1R (AZD2691), and COX-1/5-LO ( ). .. Using the same live-cell proliferation assay we developed in the previous study, we confirmed the 5-point concentration-response profiles (0.1–10.0 μM) in three independent manufacturing lots of Article Title: Nilotinib impairs relaxation and temporal electro-mechanical integrity in human iPS-derived cardiomyocyte sheets. Article Snippet: Introduction: Nilotinib, an anti-tumor tyrosine kinase inhibitor against BCR-ABL1, has been clinically reported to cause QT prolongation, but currently lacks evidence for a risk of torsade de pointes.. Indeed, it is poorly understood why nilotinib rarely induces torsade de pointes.. Methods and results: We adopted two-dimensional human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) sheets to examine effects of nilotinib on their electrophysiological and mechanical properties besides intracellular calcium (Ca2+) dynamics. Control:Article Title: Development of a workflow for in vitro on– and off-target cytotoxicity assessment of CAR T cell therapies to support first-in-human clinical trials: An orthogonal approach using human induced pluripotent stem cell-derived cells as a surrogate for normal vital organ systems Article Snippet: With the exception of iCell GABANeurons and iCell GlutaNeurons on impedance plates, taken together, these data indicated that all hiPSC-derived cell types behaved as advertised in terms of morphology, cell type-specific protein expression, and impedance in both prescribed medium and co-culture medium. .. For the case study described below, co-cultures of iCell endothelial cells, iCell hepatocytes, Microelectrode Array:Article Title: Identifying and establishing the critical elements of a human cardiac in-vitro model for studying type-II diabetes Article Snippet: .. Subsequently, other:Article Title: Identifying and establishing the critical elements of a human cardiac in-vitro model for studying type-II diabetes Article Snippet: Time-lapse images of beating cardiac cells ( Article Title: Development of a workflow for in vitro on– and off-target cytotoxicity assessment of CAR T cell therapies to support first-in-human clinical trials: An orthogonal approach using human induced pluripotent stem cell-derived cells as a surrogate for normal vital organ systems Article Snippet: The cells were washed twice in |